[
  {
    "ts": null,
    "headline": "Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck",
    "summary": "SAN DIEGO, August 05, 2025--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced the dosing of the first patient in its TRACTr collaboration with Merck, known as MSD outside of the United States and Canada",
    "url": "https://finnhub.io/api/news?id=e59e50a0aaa75d7975a9661ebe3c0f054fbcf5407c909a4efeb8a686628c6fdb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754424300,
      "headline": "Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck",
      "id": 136217707,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "SAN DIEGO, August 05, 2025--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced the dosing of the first patient in its TRACTr collaboration with Merck, known as MSD outside of the United States and Canada",
      "url": "https://finnhub.io/api/news?id=e59e50a0aaa75d7975a9661ebe3c0f054fbcf5407c909a4efeb8a686628c6fdb"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis Inc. (ZTS): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Zoetis Inc. on Bob’s Payment Stock Substack by Bob Hammel. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc.’s share was trading at $151.81 as of August 4th. ZTS’s trailing and forward P/E were 27.25 and 24.57, respectively according to Yahoo Finance. Zoetis remains a dominant […]",
    "url": "https://finnhub.io/api/news?id=d8c89af22dbdc1369e5820b80aef6dd6926cf5866f304edf65c4aeae5a8862ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754416588,
      "headline": "Zoetis Inc. (ZTS): A Bull Case Theory",
      "id": 136217177,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Zoetis Inc. on Bob’s Payment Stock Substack by Bob Hammel. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc.’s share was trading at $151.81 as of August 4th. ZTS’s trailing and forward P/E were 27.25 and 24.57, respectively according to Yahoo Finance. Zoetis remains a dominant […]",
      "url": "https://finnhub.io/api/news?id=d8c89af22dbdc1369e5820b80aef6dd6926cf5866f304edf65c4aeae5a8862ef"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=02b1a3fa0defaf425707ff43498bed59b576b60e9f9137d2cdacd7a7017161c0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754411640,
      "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "id": 136235496,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=02b1a3fa0defaf425707ff43498bed59b576b60e9f9137d2cdacd7a7017161c0"
    }
  },
  {
    "ts": null,
    "headline": "Why Investors Should Expect The July CPI To Tick Higher",
    "summary": "Tariff risks remain high for July CPI. A higher CPI print increases the likelihood of a Fed rate cut. Check out the expected implications of July CPI report.",
    "url": "https://finnhub.io/api/news?id=501f33d90b61d9605caccb84cfd16a2c41334b19f8bf3760b5797b84147ce991",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754399705,
      "headline": "Why Investors Should Expect The July CPI To Tick Higher",
      "id": 136214557,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2211730607/image_2211730607.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Tariff risks remain high for July CPI. A higher CPI print increases the likelihood of a Fed rate cut. Check out the expected implications of July CPI report.",
      "url": "https://finnhub.io/api/news?id=501f33d90b61d9605caccb84cfd16a2c41334b19f8bf3760b5797b84147ce991"
    }
  },
  {
    "ts": null,
    "headline": "Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?",
    "summary": "EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.",
    "url": "https://finnhub.io/api/news?id=74aadfdf38f85f372d0b0324082794bf0413beb87e972767faadab80e17d84a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754399400,
      "headline": "Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?",
      "id": 136214444,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.",
      "url": "https://finnhub.io/api/news?id=74aadfdf38f85f372d0b0324082794bf0413beb87e972767faadab80e17d84a9"
    }
  },
  {
    "ts": null,
    "headline": "Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1",
    "summary": "SYDNEY, AUSTRALIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and constructive feedback from the US Food and Drug Administration (FDA), regarding future clinical development of its first-in-class MHC Class II agonist, eftilagimod alfa (“efti”), for first line treatment of recurrent/metastatic head and neck squamous cel",
    "url": "https://finnhub.io/api/news?id=0688c2b3b3a751d659f6849a8418c70b3fe1b88d8410c295a13aeeca29443104",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754395200,
      "headline": "Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1",
      "id": 136212351,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "SYDNEY, AUSTRALIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and constructive feedback from the US Food and Drug Administration (FDA), regarding future clinical development of its first-in-class MHC Class II agonist, eftilagimod alfa (“efti”), for first line treatment of recurrent/metastatic head and neck squamous cel",
      "url": "https://finnhub.io/api/news?id=0688c2b3b3a751d659f6849a8418c70b3fe1b88d8410c295a13aeeca29443104"
    }
  },
  {
    "ts": null,
    "headline": "Income Strategy: I'm Buying 2 Elite Mispriced Dividends",
    "summary": "Discover 2 undervalued stocks with strong yields, competitive edges, and capital returns.",
    "url": "https://finnhub.io/api/news?id=12b973a616b26b21e9a10ec3440365847920eda8a6a07679ed7b00f6913fe9e3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754388190,
      "headline": "Income Strategy: I'm Buying 2 Elite Mispriced Dividends",
      "id": 136212728,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1462296278/image_1462296278.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover 2 undervalued stocks with strong yields, competitive edges, and capital returns.",
      "url": "https://finnhub.io/api/news?id=12b973a616b26b21e9a10ec3440365847920eda8a6a07679ed7b00f6913fe9e3"
    }
  },
  {
    "ts": null,
    "headline": "Residual DNA Testing Global Market Forecast to 2030 | Novel Modalities, Emerging Markets Growth, Continuous Processing Integration, and Rising CRO/CDMO Outsourcing",
    "summary": "The residual DNA testing market is set to grow from USD 0.28 billion in 2025 to USD 0.37 billion by 2030, with a 6.0% CAGR. Key factors driving this growth include increasing biologics and biosimilars approvals and stringent regulatory frameworks. PCR technology holds the largest market share due to its high precision. The pharmaceutical and biotechnology sector dominates the demand for testing services. North America leads the market, fueled by robust R&D investments. Major players include Ther",
    "url": "https://finnhub.io/api/news?id=cf0a6d278a3ac55ee3a74c208b97ce2f74109b32cbb564291bfcfd3e2d89c286",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754382900,
      "headline": "Residual DNA Testing Global Market Forecast to 2030 | Novel Modalities, Emerging Markets Growth, Continuous Processing Integration, and Rising CRO/CDMO Outsourcing",
      "id": 136212352,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The residual DNA testing market is set to grow from USD 0.28 billion in 2025 to USD 0.37 billion by 2030, with a 6.0% CAGR. Key factors driving this growth include increasing biologics and biosimilars approvals and stringent regulatory frameworks. PCR technology holds the largest market share due to its high precision. The pharmaceutical and biotechnology sector dominates the demand for testing services. North America leads the market, fueled by robust R&D investments. Major players include Ther",
      "url": "https://finnhub.io/api/news?id=cf0a6d278a3ac55ee3a74c208b97ce2f74109b32cbb564291bfcfd3e2d89c286"
    }
  },
  {
    "ts": null,
    "headline": "Cancer Vaccine Research Report 2025-2035 | Market Accelerates with Key Players Like Merck and Moderna, Backed by Pharma-Biotech Collaborations and Academic Partnerships",
    "summary": "The global cancer vaccine market is experiencing robust growth driven by rising cancer cases, advancements in immunotherapy, and novel vaccine development technologies. Both preventive (e.g., HPV, HBV) and therapeutic vaccines are gaining traction, supported by increased R&D investments, especially in mRNA platforms and neoantigen vaccines. Innovations like AI and genome sequencing are enhancing personalized therapies, while FDA approvals boost confidence in clinical efficacy. With strong health",
    "url": "https://finnhub.io/api/news?id=a2f69b323d53e66fb01bddee62c9fbb8526467370f91cdf85555ed9ea70d5d9d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754380980,
      "headline": "Cancer Vaccine Research Report 2025-2035 | Market Accelerates with Key Players Like Merck and Moderna, Backed by Pharma-Biotech Collaborations and Academic Partnerships",
      "id": 136212353,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The global cancer vaccine market is experiencing robust growth driven by rising cancer cases, advancements in immunotherapy, and novel vaccine development technologies. Both preventive (e.g., HPV, HBV) and therapeutic vaccines are gaining traction, supported by increased R&D investments, especially in mRNA platforms and neoantigen vaccines. Innovations like AI and genome sequencing are enhancing personalized therapies, while FDA approvals boost confidence in clinical efficacy. With strong health",
      "url": "https://finnhub.io/api/news?id=a2f69b323d53e66fb01bddee62c9fbb8526467370f91cdf85555ed9ea70d5d9d"
    }
  },
  {
    "ts": null,
    "headline": "Let’s make a deal? Big Pharma execs express varying views on their M&A future",
    "summary": "Pharma executives are keeping their eyes open for dealmaking opportunities as every company has its own battles to fight.",
    "url": "https://finnhub.io/api/news?id=cf3d1a6c784f17c1c4ea8d2bddd1d76fda7e9e741f9908263e088886afea14d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754380800,
      "headline": "Let’s make a deal? Big Pharma execs express varying views on their M&A future",
      "id": 136214982,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pharma executives are keeping their eyes open for dealmaking opportunities as every company has its own battles to fight.",
      "url": "https://finnhub.io/api/news?id=cf3d1a6c784f17c1c4ea8d2bddd1d76fda7e9e741f9908263e088886afea14d7"
    }
  },
  {
    "ts": null,
    "headline": "SCHD: Wouldn't Call It Dead Money",
    "summary": "SCHD: Wouldn't Call It Dead Money",
    "url": "https://finnhub.io/api/news?id=bc49ec13cab3ef87b4d547a132da3f85345374f2f614cfeb9f7b8ed5f2b2cbbd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754377380,
      "headline": "SCHD: Wouldn't Call It Dead Money",
      "id": 136207962,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=bc49ec13cab3ef87b4d547a132da3f85345374f2f614cfeb9f7b8ed5f2b2cbbd"
    }
  }
]